The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s (SNY) said FDA lifted a hold on a trial to test over-the-counter use of its Eli-Lilly (LLY)-partnered erectile ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

French pharma major Sanofi's participation at the JP Morgan Healthcare Conference was marked by a comprehensive overview of its position in 2024 and its strategic vision for the future.

It sells products through independent distributors ... the company came under the control of Sanofi-Synthelabo, now called sanofi-aventis which acquired indirect control 50.1% of the companys ...